logo
Share SHARE
FONT-SIZE Plus   Neg

CoreLogic Sees Q4, FY11 Results To Exceed High End Of Prior Guidance

CoreLogic Inc. (CLGX) said that it expects fourth-quarter and full-year results to exceed high end of prior adjusted revenue, and adjusted earnings per share guidance.

Previously, the company had expected fiscal year 2011 adjusted earnings to be in the range of $0.75-$0.80 per share and adjusted revenues of $1.350 billion - $1.370 billion. Analysts polled by Thomson Reuters expect the company to report earnings of $0.74 per share on revenues of $1.47 billion for fiscal 2011. Analysts' estimates typically exclude special items.

Looking ahead for full-year 2012, the company expects adjusted earnings to be in the range of $0.95 - $1.05, and adjusted revenue of $1.425 billion - $1.475 billion. Analysts expect the company to report earnings of $0.87 per share on revenues of $1.44 billion for fiscal 2012.

CoreLogic expects to report its fourth quarter and full-year results after the market close on February 27, 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
The Coca-Cola Company (KO) reported a profit for the first-quarter of 2017 that declined 20 percent from the prior year. Net revenues declined 11%, reflecting unfavorable impacts from structural changes of 10% and foreign currency of 1%. The company remains on track to deliver its underlying revenue and profit targets for the full year. Eli Lilly and Co. (LLY) reported a loss for the first quarter of 2017 compared to profit in the prior year, primarily hurt by lower operating income, partially offset by higher other income. But, quarterly revenue increased 7 percent, driven by 9 percent pharmaceutical volume growth from Trulicity, Taltz and other new products. Capricor Therapeutics, Inc., a clinical-stage biotechnology company for cardiac and other medical conditions, announced Tuesday positive six-month results from the randomized phase I/II HOPE clinical trial in Duchenne muscular dystrophy or DMD. The HOPE clinical trial was designed to evaluate the safety and exploratory efficacy of CAP-1002.
comments powered by Disqus
Follow RTT